Chukwunonso Kingsley Nwabufo

Mr. Chukwunonso Kingsley Nwabufo

Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2021 in Drug Metabolism Reviews
Verified
Journal Article
Open access
LRLaura E. Russell
Laura E. Russell
YZYitian Zhou
Yitian Zhou
AAAhmed A. Almousa
Ahmed A. Almousa
JSJasleen K. Sodhi
Jasleen K. Sodhi
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
VLVolker Lauschke
Volker Lauschke
Pharmacogenetic research has resulted in the identification of a multitude of genetic variants that impact drug response or toxicity. These polymorphisms are mostly common and have been included as actionable information in the labels of numerous drugs. In addition to common variants, recent advances in Next Generation Sequencing (NGS) technologies have resulted in the identification of a plethora of rare and population-specific pharmacogenetic variations with unclear functional consequences that are not accessible by conventional forward genetics strategies. In this review, we discuss how comprehensive sequencing information can be translated into personalized pharmacogenomic advice in the age of NGS. Specifically, we provide an update of the functional impacts of rare pharmacogenetic variability and how this information can be leveraged to improve pharmacogenetic guidance. Furthermore, we critically discuss the current status of implementation of pharmacogenetic testing across drug development and layers of care. We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data for personalized clinical decision-support.

13 July 2022 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun

18 August 2023 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
ImmunoGen developed mirvetuximab soravtansine as an antibody–drug conjugate comprising of a humanized anti-folate receptor—α (FRα) monoclonal antibody of IgG1k subtype, a cleavable linker, and a cytotoxic payload, DM4. Mirvetuximab soravtansine was granted accelerated approval by the US FDA on November 14, 2022, for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1—3 prior systemic treatment regimens. The approval of mirvetuximab soravtansine represents a breakthrough for addressing the unmet medical needs of ovarian cancer, especially for up to 80% of patients who relapse and become resistant to platinum-based chemotherapy, resulting in poor prognosis and limited treatment options. However, it is my impression that addressing several pharmacological factors could improve the safety and efficacy of mirvetuximab soravtansine. This article summarizes the current pharmacological profile of mirvetuximab soravtansine and provides an expert opinion on pharmacological strategies for optimizing its safety and efficacy profile for the treatment of platinum-resistant ovarian cancer.

3 July 2021 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
ATAarzoo Thakur
Aarzoo Thakur
ZTZhiyuan Tan
Zhiyuan Tan
TKTsubasa Kameyama
Tsubasa Kameyama
EEEman El-Khateeb
Eman El-Khateeb
SNShakti Nagpal
Shakti Nagpal
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
A reliable, rapid, and effective bioanalytical method is essential for the determination of the pharmacokinetic, pharmacodynamic, and toxicokinetic parameters that inform the safety and efficacy profile of investigational drugs. The overall goal of bioanalytical method development is to elucidate the procedure and operating conditions under which a method can sufficiently extract, qualify, and/or quantify the analyte(s) of interest and/or their metabolites for the intended purpose. Given the difference in the physicochemical properties of small and large molecule drugs, different strategies need to be adopted for the development of an effective and efficient bioanalytical method. Herein, we provide an overview of different sample preparation strategies, analytical platforms, as well as procedures for achieving high-throughput for bioanalysis of small and large molecule drugs.

26 September 2022 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
RBReina Bendayan
Reina Bendayan

26 May 2020 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
LRLaura E. Russell
Laura E. Russell
MSMary Schleiff
Mary Schleiff
EGEric Gonzalez
Eric Gonzalez
ABAaron G. Bart
Aaron G. Bart
FBFabio Broccatelli
Fabio Broccatelli
JSJasleen Sodhi
Jasleen Sodhi
The 12th International Society for the Study of Xenobiotics (ISSX) meeting, held in Portland, OR, USA from July 28 to 31, 2019, was attended by diverse members of the pharmaceutical sciences community. The ISSX New Investigators Group provides learning and professional growth opportunities for student and early career members of ISSX. To share meeting content with those who were unable to attend, the ISSX New Investigators herein elected to highlight the “Advances in the Study of Drug Metabolism” symposium, as it engaged attendees with diverse backgrounds. This session covered a wide range of current topics in drug metabolism research including predicting sites and routes of metabolism, metabolite identification, ligand docking, and medicinal and natural products chemistry, and highlighted approaches complemented by computational modeling. In silico tools have been increasingly applied in both academic and industrial settings, alongside traditional and evolving in vitro techniques, to strengthen and streamline pharmaceutical research. Approaches such as quantum mechanics simulations facilitate understanding of reaction energetics toward prediction of routes and sites of drug metabolism. Furthermore, in tandem with crystallographic and orthogonal wet lab techniques for structural validation of drug metabolizing enzymes, in silico models can aid understanding of substrate recognition by particular enzymes, identify metabolic soft spots and predict toxic metabolites for improved molecular design. Of note, integration of chemical synthesis and biosynthesis using natural products remains an important approach for identifying new chemical scaffolds in drug discovery. These subjects, compiled by the symposium organizers, presenters, and the ISSX New Investigators Group, are discussed in this review.